The starting point itself is not a judgment call. Tirzepatide has one labeled starting dosage for every indication, and a switch begins there. What a prescriber actually decides is whether the move is warranted at all, which indication is being treated, whether anything contraindicates it, and what the transition timing should be.
The indications are not interchangeable, and that drives the decision
Reading both labels side by side shows why a switch is sometimes clinically indicated rather than a matter of preference. Zepbound is indicated, alongside a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or with overweight plus a weight-related condition, and separately to treat moderate to severe obstructive sleep apnea in adults with obesity.
That second indication has no counterpart on the semaglutide side. A patient with untreated moderate to severe sleep apnea and obesity has a labeled reason to be on tirzepatide that has nothing to do with dissatisfaction. The supporting evidence came from two phase 3 randomized trials in adults with moderate to severe obstructive sleep apnea and obesity, one in people not using positive airway pressure and one in people already on it, in which tirzepatide reduced the apnea-hypopnea index by roughly 25 to 29 events per hour against about 5 on placebo over 52 weeks.
The traffic runs the other way too. The Wegovy label carries indications tirzepatide does not: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis under accelerated approval, and weight reduction in patients aged 12 and older. For a patient whose cardiovascular history is the reason they are on treatment, moving away from semaglutide gives something up.
What gets rescreened before the first new dose
| Check | Why it comes up again on a switch |
|---|---|
| Personal or family history of medullary thyroid carcinoma, or MEN 2 | Contraindicated on both labels under a boxed warning, so clearance on one is not clearance in general |
| Prior serious hypersensitivity | Reactions to one molecule do not predict the other, and each label contraindicates its own |
| History of pancreatitis or gallbladder disease | Both labels warn on acute pancreatitis and acute gallbladder disease |
| Severe gastroparesis | Tirzepatide is not recommended in patients with severe gastroparesis |
| Insulin or an insulin secretagogue in use | Hypoglycemia risk rises, and doses may need adjusting as exposure changes |
| Diabetes of any kind | Blood glucose monitoring is specified before and during treatment |
| Which product was actually being taken | Compounded preparations vary by pharmacy and are not FDA-approved |
Reading the comparative evidence without overreading it
Two genuine head-to-head trials exist, and both should be read for what they measured. SURPASS-2 randomized 1,879 patients with type 2 diabetes to tirzepatide at 5, 10 or 15 mg or to semaglutide at 1 mg, with change in glycated hemoglobin as the primary endpoint. That semaglutide dose belongs to diabetes treatment, not to the obesity range.
SURMOUNT-5 is closer to the question. It randomized 751 adults with obesity and without type 2 diabetes, open-label, to the maximum tolerated dose of tirzepatide, 10 or 15 mg, or of semaglutide, 1.7 or 2.4 mg, for 72 weeks. Mean weight change was 20.2 percent with tirzepatide and 13.7 percent with semaglutide.
A group average does not predict one person’s response, and a trial of people starting fresh does not describe someone already months into treatment on the comparator. The separate placebo-controlled programs, STEP-1 and SURMOUNT-1, are frequently quoted against each other; they were different trials with different populations, and the comparison is indirect.
Patients reading these trials secondhand often want a single page that frames the two drugs together, and the telehealth market supplies that unevenly. LillyDirect and NovoCare Pharmacy speak only for their own manufacturer’s product, whereas prescriber-led services such as Ro publish head-to-head material, HealthRX among them with a Wegovy vs Zepbound breakdown that separates the trial averages from what an individual switch involves. A resource that keeps that distinction visible is more useful than one quoting a single headline percentage.
Reasons that hold up, and reasons that do not
Coverage and supply carry real weight, since a product that cannot be obtained is not a treatment. A new indication belonging to only one label is a strong reason, sleep apnea being the current example. A documented plateau, meaning a maintenance dose reached and held for months with no further change, is a legitimate clinical observation.
Weaker reasons are equally identifiable. Escaping gastrointestinal effects rarely works, because both drugs act on the GLP-1 receptor and produce mainly the same category of effect, and the switch restarts the escalation phase where those effects concentrate. Concluding at a starting dose that a drug has failed is a judgment made too early. And a headline percentage from a trial is a population figure, not a forecast.
Where the transition question gets settled
The interval between the last dose of one product and the first of the other is a prescribing decision with a written basis, since the tirzepatide labeling states that coadministration with any GLP-1 receptor agonist is not recommended. It depends on what was last taken and when, and it is not a matter for estimation.
Who answers that question depends on how care is arranged. An endocrinology or primary care practice has the chart, the laboratory results and the other prescriptions in view. Manufacturer channels such as LillyDirect and NovoCare Pharmacy dispense a single company’s products and are not positioned to advise on moving between them. Telehealth prescribers including Ro, Hims & Hers, LifeMD, Sesame and WeightWatchers Clinic each run their own intake, and the practical test of any of them is whether a named clinician takes responsibility for a transition plan. Where a service advertises supervised compounded medication at a flat monthly price, it is worth asking the provider behind it how transitions between molecules are handled and who signs off on them before committing on price alone.
Setting the terms for judging it later
Good practice fixes the evaluation point at the start. That means agreeing what dose the plan is climbing toward, roughly when it should be reached, what result would count as success and what would trigger a change of approach. Without that, a transition gets relitigated every few weeks against a moving standard, usually during the escalation months when nothing meaningful can be concluded yet.
It also means recording the history before it fades: highest dose reached on the previous product, how long it was held, the trajectory at that dose, and which effects appeared at which step. That record is the difference between a prescriber hearing that a drug stopped working and one seeing a maintenance dose sustained for five months against a flat line.
Frequently asked questions
Does a favorable head-to-head trial mean most people should switch?
No. SURMOUNT-5 measured average outcomes in adults starting treatment, not in people already established on the comparator. Averages describe groups. Individual response, tolerability, the indication being treated and what coverage will pay for all sit outside the trial result.
Who is unlikely to be started on tirzepatide?
Anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, which is a contraindication under the boxed warning, and anyone with known serious hypersensitivity to tirzepatide. Severe gastroparesis is a separate reason the labeling advises against use.
Why does sleep apnea change the conversation?
Because it is a labeled indication on one product and not the other. Treating moderate to severe obstructive sleep apnea in an adult with obesity gives a clinical reason for the specific molecule, which is a different argument from preferring it, and it usually changes the coverage discussion as well.
Does the labeling explain how to switch between the two?
No. Each prescribing information describes its own product, and the semaglutide label’s switching section covers only its injection and tablet forms. Nothing crosses the two molecules, which is why the transition plan comes from a prescriber rather than from a document.
What if the previous product was compounded?
The prescriber needs the exact active ingredient, concentration and dispensing pharmacy. Compounded preparations are not FDA-approved and are not standardized between pharmacies, so what was actually taken cannot be inferred from the name on the vial alone.
